Company intelligence / Profile preview

Verinomics

New Haven, Connecticut, United Statesverinomics.com ↗

Ownership: Private
Employees: ~17
Development stage: Commercial

Overview

Verinomics has developed and deployed two proprietary platforms—Genesis™ for transgene-free gene editing and Genova™ for AI-powered breeding acceleration. These platforms are being used in strategic partnerships to deliver improved specialty crop varieties with enhanced traits such as disease resistance and self-fertility. Early results include successful collaborations with major nurseries like Burchell Nursery for almonds and Pinnacle Seed for leafy greens.

Therapeutic areas: Other
Modalities: Gene editing (transgene-free)Genomic selectionAI-driven trait identification
Industry: Non-Drug Biotech

Partnerships

Burchell Nursery (almond production/self-compatible almond varieties)Pinnacle Seed (leafy green innovation/disease-resistant varieties)

Beyond the preview

Go deeper on Verinomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verinomics.

Explore the full profile